1533426-72-0

Basic information

• Product Name: SCR7
• Synonyms: 2,3-Dihydro-5,6-bis[(E)-(phenylmethylene)amino]-2-thioxo-4(1H)-pyrimidinone;SCR7;5,6-bis((E)-benzylideneamino)-2-mercaptopyrimidin-4-ol;5,6-bis((E)-benzylideneamino)-2-thioxo-2,3-dihydropyrimidin-4(1H)-one
• CAS NO: 1533426-72-0
• Molecular Formula: C18H14N4OS
• Molecular Weight: 334.4
• EINECS: -0
• Product Categories: Inhibitors
• Mol File: 1533426-72-0.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• Density: 1.27±0.1 g/cm3(Predicted)
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 7.93±0.25(Predicted)
• CAS DataBase Reference: SCR7(CAS DataBase Reference)
• NIST Chemistry Reference: SCR7(1533426-72-0)
• EPA Substance Registry System: SCR7(1533426-72-0)

Safety Data

• Hazardous Substances Data: 1533426-72-0(Hazardous Substances Data)

Usage

Description

SCR7 is a small molecule that selectively inhibits one of the DNA double strand break (DSB) repair pathways, non-homologous end joining (NHEJ). It has the potential to be a promising pharmaceutical candidate for various applications in the field of cancer treatment.

Uses

Used in Anticancer Applications:
SCR7 is used as an anti-cancer agent for selectively inhibiting the non-homologous end joining (NHEJ) repair pathway, which plays a crucial role in the repair of DNA double strand breaks. By inhibiting this pathway, SCR7 can potentially enhance the effectiveness of cancer treatments that induce DNA damage, such as radiation therapy and certain chemotherapy drugs.
Used in Drug Development:
SCR7 is used as a lead compound in the development of novel cancer therapeutics. Its selective inhibition of the NHEJ repair pathway can be exploited to design more effective cancer treatments that target specific molecular mechanisms within cancer cells.
Used in Research:
SCR7 is used as a research tool to study the role of the NHEJ repair pathway in cancer cell survival and resistance to treatment. Understanding the molecular mechanisms underlying the action of SCR7 can provide valuable insights into the development of new cancer therapies and the identification of potential biomarkers for patient stratification and treatment response prediction.
Used in Combination Therapies:
SCR7 is used in combination with other cancer treatments, such as radiation therapy and chemotherapy, to enhance their effectiveness by inhibiting the NHEJ repair pathway and increasing the accumulation of DNA damage in cancer cells.
Used in Personalized Medicine:
SCR7 is used as a potential component of personalized cancer treatment strategies, where its application can be tailored to individual patients based on their specific genetic and molecular profiles. This approach may help to improve treatment outcomes and reduce side effects by targeting cancer cells more precisely.